• Breast cancer

Aromasin Generic Name & Formulations

General Description

Exemestane 25mg; tabs.

Pharmacological Class

Aromatase inhibitor.

How Supplied



Aromasin Indications


In postmenopausal women: adjuvant treatment of estrogen-receptor positive early breast cancer after 2–3yrs of tamoxifen therapy to complete a total of 5yrs of hormonal therapy; advanced breast cancer with disease progression after tamoxifen therapy.

Aromasin Dosage and Administration


Give after a meal. 25mg once daily. Concomitant strong CYP3A4 inducers (see Interactions): 50mg once daily.


Not established.

Aromasin Contraindications

Not Applicable

Aromasin Boxed Warnings

Not Applicable

Aromasin Warnings/Precautions


Not for treatment in premenopausal women. Osteoporosis; assess bone mineral density (BMD) at start of treatment. Monitor all patients for BMD loss and treat as appropriate. Perform routine assessment of Vit. D levels prior to initiation; supplement if deficient. Hepatic or renal impairment. Embryo-fetal toxicity. Pregnancy. Females of reproductive potential: should undergo pregnancy testing within 7 days prior to initiation; use effective contraception during and for 1 month after final dose. Nursing mothers: not recommended (during and for 1 month after final dose).

Aromasin Pharmacokinetics

See Literature

Aromasin Interactions


Antagonized by strong CYP3A4 inducers (eg, rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s wort).

Aromasin Adverse Reactions

Adverse Reactions

Hot flashes, fatigue, arthralgia, headache, insomnia, increased sweating, nausea, increased appetite; reductions in BMD.

Aromasin Clinical Trials

See Literature

Aromasin Note

Not Applicable

Aromasin Patient Counseling

See Literature